Ulrika Birgersdotter-Green
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ulrika Birgersdotter-Green has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Travis Pollema
Department of Cardiology University of California San Diego La Jolla California USA
3 shared publications- Douglas Darden
Kansas City Heart Rhythm Institute, Overland Park, USA
2 shared publications Gordon Ho
Department of Cardiology University of California San Diego La Jolla California USA
2 shared publications- Adrian Baranchuk
Universidad Abierta Interamericana (UAI)
1 shared publication Alvaro Manrique Garcia
1 shared publication- Anish Amin
Riverside Methodist Hospital, Upper Arlington, OH (A.A.).
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (11) , e3046-e3047
Initial experience of atrial helix-fixation leadless pacemakers with extended battery longevity
- 27 April 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (11) , e3046-e3047
Open AccessInitial experience of atrial helix-fixation leadless pacemakers with extended battery longevity
- Open Access
- 15 November 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 61-69
Atrial fibrillation detection performance of an insertable cardiac monitor: Results from an Assert-IQ post-market clinical study and a novel artificial intelligence algorithm
- 15 November 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 61-69
Open AccessAtrial fibrillation detection performance of an insertable cardiac monitor: Results from an Assert-IQ post-market clinical study and a novel artificial intelligence algorithm
- 5 July 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (9) , 1232-1240
Computed tomography predictors of increased transvenous lead extraction difficulty
Background: The ability of computed tomography (CT) characteristics to predict the difficulty of transvenous lead extraction (TLE) is an evolving subject.Objective: To identify CT characteristics associated with increased TLE difficulty.Methods: All consecutive patients undergoing TLE at the University of California San Diego from January 2018 to February 2022 were analyzed, utilizing the UC San Diego Lead Extraction Registry. Patients underwent cardiac‐gated chest CT scans with intravenous contrast; all scans were reviewed by a single radiologist. Lead extraction was performed per standard institutional protocol with the initial use of a laser sheath and crossover to a mechanical sheath as needed. Multivariable linear and logistic regression analyses were performed to identify predictors of individual lead‐removal fluoroscopy time and mechanical sheath use, as markers of extraction difficulty.Results: A total of 343 patients were analyzed. The mean age of the study population was 63.8 ± 15.4 years; 71% were male. The mean lead dwell‐in duration was 8.6 ± 5.7 years. In multivariable linear regression analysis, venous occlusion detected on CT was independently associated with higher individual lead‐removal fluoroscopy time (p = 0.004), when adjusting for clinical characteristics such as lead dwell time. In multivariable logistic regression analysis, calcification and venous occlusion were independently associated with a higher need for mechanical sheath use during TLE (odds ratio:5.08, p < 0.001, 95% CI: 2.54–10.46) and (odds ratio:3.72, p < 0.001, 95% CI: 1.89–7.35), respectively.Conclusion: In patients undergoing TLE, venous occlusion identified by chest CT is associated with increased fluoroscopy time. Patients with lead‐associated calcification or venous occlusion detected by chest CT are each five and three times more likely to require crossover from laser to a mechanical sheath.
- 5 July 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (9) , 1232-1240
Computed tomography predictors of increased transvenous lead extraction difficulty
Background: The ability of computed tomography (CT) characteristics to predict the difficulty of transvenous lead extraction (TLE) is an evolving subject.Objective: To identify CT characteristics associated with increased TLE difficulty.Methods: All consecutive patients undergoing TLE at the University of California San Diego from January 2018 to February 2022 were analyzed, utilizing the UC San Diego Lead Extraction Registry. Patients underwent cardiac‐gated chest CT scans with intravenous contrast; all scans were reviewed by a single radiologist. Lead extraction was performed per standard institutional protocol with the initial use of a laser sheath and crossover to a mechanical sheath as needed. Multivariable linear and logistic regression analyses were performed to identify predictors of individual lead‐removal fluoroscopy time and mechanical sheath use, as markers of extraction difficulty.Results: A total of 343 patients were analyzed. The mean age of the study population was 63.8 ± 15.4 years; 71% were male. The mean lead dwell‐in duration was 8.6 ± 5.7 years. In multivariable linear regression analysis, venous occlusion detected on CT was independently associated with higher individual lead‐removal fluoroscopy time (p = 0.004), when adjusting for clinical characteristics such as lead dwell time. In multivariable logistic regression analysis, calcification and venous occlusion were independently associated with a higher need for mechanical sheath use during TLE (odds ratio:5.08, p < 0.001, 95% CI: 2.54–10.46) and (odds ratio:3.72, p < 0.001, 95% CI: 1.89–7.35), respectively.Conclusion: In patients undergoing TLE, venous occlusion identified by chest CT is associated with increased fluoroscopy time. Patients with lead‐associated calcification or venous occlusion detected by chest CT are each five and three times more likely to require crossover from laser to a mechanical sheath.
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Substernal lead removal: experience from the EV ICD pivotal study
Background: The extravascular implantable cardioverter defibrillator (EV ICD) has recently emerged as a new option for guideline indicated ICD patients. Previous study results from the EV ICD Pilot and Pivotal studies have demonstrated that the device can provide safe and effective therapy through chronic follow up. However, less has been reported regarding EV ICD lead removal. Purpose: To report on the experience of lead removal in the EV ICD Pivotal Study. Methods: The EV ICD Pivotal study was an international, prospective, single-arm, premarket clinical study. Patients with a class I or IIa indication for a single-chamber ICD per ESC or ACC/AHA/HRS guidelines were enrolled. Lead removal summary data was reported. Results: Of 316 patients with an implant attempt, (74.7% male, age 53.8±13.1 years, 82% primary prevention, LVEF of 38.9%±15.4%, and NYHA Class I [23.7%] or II/III [65.5%]) 299 were fully implanted; 17 (5.7%) of which had a lead removal procedure (14–752 days post-implant, at 13 sites) with 3 of them having been implanted for more than 1 year. Reasons for lead removal were lead dislodgement (n=7), infection (n=5), high impedance alert due to lead fracture (n=2), pacing indication (n=1), cardiac transplant (n=1), or scheduled sternotomy (n=1). New EV ICD leads were placed in 7/17 (41.2%) patients. No serious adverse events were adjudicated as related to the explant procedures. There was a single observation of incision site haemorrhage, that was resolved with wound care. Additional details on lead removal will be included at the time of presentation. Conclusions: The EV ICD lead was successfully removed 14-752 days post implant. Nine patients were re-implanted with either extravascular or transvenous systems. Longer term extraction data collection is ongoing through the EV ICD Pivotal study and through the EV ICD post-approval study and will continue to provide additional insights.Lead removed 24 months post-implant.
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessSubsternal lead removal: experience from the EV ICD pivotal study
Background: The extravascular implantable cardioverter defibrillator (EV ICD) has recently emerged as a new option for guideline indicated ICD patients. Previous study results from the EV ICD Pilot and Pivotal studies have demonstrated that the device can provide safe and effective therapy through chronic follow up. However, less has been reported regarding EV ICD lead removal. Purpose: To report on the experience of lead removal in the EV ICD Pivotal Study. Methods: The EV ICD Pivotal study was an international, prospective, single-arm, premarket clinical study. Patients with a class I or IIa indication for a single-chamber ICD per ESC or ACC/AHA/HRS guidelines were enrolled. Lead removal summary data was reported. Results: Of 316 patients with an implant attempt, (74.7% male, age 53.8±13.1 years, 82% primary prevention, LVEF of 38.9%±15.4%, and NYHA Class I [23.7%] or II/III [65.5%]) 299 were fully implanted; 17 (5.7%) of which had a lead removal procedure (14–752 days post-implant, at 13 sites) with 3 of them having been implanted for more than 1 year. Reasons for lead removal were lead dislodgement (n=7), infection (n=5), high impedance alert due to lead fracture (n=2), pacing indication (n=1), cardiac transplant (n=1), or scheduled sternotomy (n=1). New EV ICD leads were placed in 7/17 (41.2%) patients. No serious adverse events were adjudicated as related to the explant procedures. There was a single observation of incision site haemorrhage, that was resolved with wound care. Additional details on lead removal will be included at the time of presentation. Conclusions: The EV ICD lead was successfully removed 14-752 days post implant. Nine patients were re-implanted with either extravascular or transvenous systems. Longer term extraction data collection is ongoing through the EV ICD Pivotal study and through the EV ICD post-approval study and will continue to provide additional insights.Lead removed 24 months post-implant.
- Open Access
- 20 December 2023
- Published by Elsevier in JACC: Advances
- Vol. 3 (2) , 100773
Contemporary Management of Cardiac Implantable Electronic Device Infection
- 20 December 2023
- Published by Elsevier in JACC: Advances
- Vol. 3 (2) , 100773
Open AccessContemporary Management of Cardiac Implantable Electronic Device Infection
- 1 March 2023
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 14 (3) , 5369-5371
An Ambulatory Approach to Atrioventricular Block in Lyme Carditis Using Temporary Permanent Pacemakers
An Ambulatory Approach to Atrioventricular Block in Lyme Carditis Using Temporary Permanent Pacemakers
- 1 March 2023
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 14 (3) , 5369-5371
An Ambulatory Approach to Atrioventricular Block in Lyme Carditis Using Temporary Permanent Pacemakers
An Ambulatory Approach to Atrioventricular Block in Lyme Carditis Using Temporary Permanent Pacemakers
- Open Access
- 21 October 2022
- Published by Elsevier in Heart Rhythm O2
- Vol. 3 (5) , 597-601
The subcutaneous implantable cardioverter-defibrillator should be reserved for niche indications
- 21 October 2022
- Published by Elsevier in Heart Rhythm O2
- Vol. 3 (5) , 597-601
Open AccessThe subcutaneous implantable cardioverter-defibrillator should be reserved for niche indications
- 1 June 2022
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 45 (7) , 853-860
Implantable loop recorder as a strategy following cardiovascular implantable electronic device extraction without reimplantation
Background Limited data exists for outcomes in patients undergoing cardiovascular implantable electronic device (CIED) transvenous lead extraction (TLE) without clear indications for device reimplantation. The implantable loop recorder (ILR) may be an effective strategy for continuous monitoring in select individuals. Objective This retrospective analysis aims to investigate patients who have undergone ILR implant following TLE without CIED reimplantation. Methods Clinical data from consecutive patients who have undergone TLE with ILR implant and without CIED reimplantation from October 2016 to May 2020 at a single center were collected. Results Among 380 patients undergoing TLE, 28 (7.7%) underwent ILR placement without CIED reimplantation. TLE indications were systemic infection (n = 13, 46.4%), pain at the site (n = 8, 28.6%), device/lead malfunction (n = 4, 14.2%), and other. Devices extracted included: dual-chamber and single-chamber pacemaker (n = 14, 50%; n = 4, 14.2%), dual-chamber implantable cardiac defibrillator (n = 10; 35.7%), and cardiac-resynchronization therapy with defibrillator (n = 1, 3.5%). Reasons for no reimplantation included no longer meeting CIED criteria (n = 14, 50%), patient preference (n = 9, 32.1%), and no clear or inappropriate indication for initial CIED implantation (n = 5, 18%). During an average of 12.3 +/- 13.1 months of follow-up, there were no lethal arrhythmias, and four (13.3%) patients underwent permanent pacemaker reimplantation due to symptomatic sinus bradycardia and atrioventricular block with syncope as discovered on ILR. Three patients died due to unknown causes (n = 1), noncardiac (n = 1), and acute coronary syndrome (n = 1). Conclusions In patients undergoing TLE without reimplantation, an ILR may be an effective monitoring strategy in patients at low risk for cardiac arrhythmia.
- 1 June 2022
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 45 (7) , 853-860
Implantable loop recorder as a strategy following cardiovascular implantable electronic device extraction without reimplantation
Background Limited data exists for outcomes in patients undergoing cardiovascular implantable electronic device (CIED) transvenous lead extraction (TLE) without clear indications for device reimplantation. The implantable loop recorder (ILR) may be an effective strategy for continuous monitoring in select individuals. Objective This retrospective analysis aims to investigate patients who have undergone ILR implant following TLE without CIED reimplantation. Methods Clinical data from consecutive patients who have undergone TLE with ILR implant and without CIED reimplantation from October 2016 to May 2020 at a single center were collected. Results Among 380 patients undergoing TLE, 28 (7.7%) underwent ILR placement without CIED reimplantation. TLE indications were systemic infection (n = 13, 46.4%), pain at the site (n = 8, 28.6%), device/lead malfunction (n = 4, 14.2%), and other. Devices extracted included: dual-chamber and single-chamber pacemaker (n = 14, 50%; n = 4, 14.2%), dual-chamber implantable cardiac defibrillator (n = 10; 35.7%), and cardiac-resynchronization therapy with defibrillator (n = 1, 3.5%). Reasons for no reimplantation included no longer meeting CIED criteria (n = 14, 50%), patient preference (n = 9, 32.1%), and no clear or inappropriate indication for initial CIED implantation (n = 5, 18%). During an average of 12.3 +/- 13.1 months of follow-up, there were no lethal arrhythmias, and four (13.3%) patients underwent permanent pacemaker reimplantation due to symptomatic sinus bradycardia and atrioventricular block with syncope as discovered on ILR. Three patients died due to unknown causes (n = 1), noncardiac (n = 1), and acute coronary syndrome (n = 1). Conclusions In patients undergoing TLE without reimplantation, an ILR may be an effective monitoring strategy in patients at low risk for cardiac arrhythmia.
- Open Access
- 1 April 2021
- Published by Elsevier in Heart Rhythm O2
- Vol. 2 (2) , 122-123
Performance and outcomes of transvenous rotational lead extraction: Results from a prospective, monitored, global clinical study—“An evolution in extraction”
- 1 April 2021
- Published by Elsevier in Heart Rhythm O2
- Vol. 2 (2) , 122-123
Open AccessPerformance and outcomes of transvenous rotational lead extraction: Results from a prospective, monitored, global clinical study—“An evolution in extraction”
- 23 July 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (10) , 2727-2729
Antitachycardia pacing: A worthy cause?
- 23 July 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (10) , 2727-2729
Antitachycardia pacing: A worthy cause?